Overview

The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

To assess the efficacy of intravitreal injection of 0.5 mg conbercept in patients with polypoidal choroidal vasculopathy (PCV) and explore the optimal route of administration.

Phase:

Phase 4

Details

Lead Sponsor:

Chengdu Kanghong Biotech Co., Ltd.
Chengdu Kanghong Biotech Co.,Ltd.